Literature DB >> 10966970

Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy.

P T Finger1.   

Abstract

AIM: To examine how tumour location affects ocular morbidity after ophthalmic plaque radiotherapy for uveal melanoma.
METHODS: 69 eyes were irradiated and followed for a mean 42 months. There were 23 anterior uveal melanomas and 46 were posterior to the equator. Anterior and posterior tumours had similar basal dimensions. Their mean apical heights were 4.8 mm (anterior) and 3.5 mm (posterior) which received a mean 88 Gy and 83.4 Gy respectively.
RESULTS: Only one patient (4%) plaqued for an anterior uveal melanoma developed secondary retinopathy (cystoid macular oedema). In contrast, 24 (52%) of the posterior choroidal melanoma patients developed retinopathy (p value <0.0001). Cataract developed in 18 (86%) eyes with phakic anterior tumour compared with seven (17%) eyes with posterior tumours (p value <0.0000). No posterior nasal tumours lost more than two lines of vision though 45% developed retinopathy.
CONCLUSION: While plaque radiation of anterior melanomas is more likely to cause reversible vision loss secondary to cataract, treatment of posterior tumours is more likely to be associated with irreversible loss because of retinopathy. Nasal location is also protective against severe loss of vision.

Entities:  

Mesh:

Year:  2000        PMID: 10966970      PMCID: PMC1723649          DOI: 10.1136/bjo.84.9.1068

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  19 in total

1.  Intraocular radiation blocking.

Authors:  P T Finger; T K Ho; D M Fastenberg; R A Hyman; E M Stroh; S Packer; H D Perry
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-09       Impact factor: 4.799

2.  The treatment of ophthalmic tumours with low-energy sources.

Authors:  R Sealy; P L le Roux; F Rapley; E Hering; D Shackleton; D Sevel
Journal:  Br J Radiol       Date:  1976-06       Impact factor: 3.039

3.  Optimization of 125I ophthalmic plaque brachytherapy.

Authors:  M A Astrahan; G Luxton; G Jozsef; P E Liggett; Z Petrovich
Journal:  Med Phys       Date:  1990 Nov-Dec       Impact factor: 4.071

4.  Long-term results of iodine 125 irradiation of uveal melanoma.

Authors:  S Packer; S Stoller; M L Lesser; F S Mandel; P T Finger
Journal:  Ophthalmology       Date:  1992-05       Impact factor: 12.079

5.  Malignant melanoblastoma of the choroid.

Authors:  H B Stallard
Journal:  Bibl Ophthalmol       Date:  1968

6.  Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma.

Authors:  M W Wilson; J L Hungerford
Journal:  Ophthalmology       Date:  1999-08       Impact factor: 12.079

7.  Radiotherapy for malignant melanoma of the choroid.

Authors:  H B Stallard
Journal:  Br J Ophthalmol       Date:  1966-03       Impact factor: 4.638

8.  Palladium 103 ophthalmic plaque radiotherapy.

Authors:  P T Finger; D M Moshfeghi; T K Ho
Journal:  Arch Ophthalmol       Date:  1991-11

9.  Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas. Twenty years' experience.

Authors:  P K Lommatzsch
Journal:  Am J Clin Oncol       Date:  1987-04       Impact factor: 2.339

10.  Palladium-103 versus iodine-125 for ophthalmic plaque radiotherapy.

Authors:  P T Finger; D Lu; A Buffa; D S DeBlasio; J L Bosworth
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-11-15       Impact factor: 7.038

View more
  15 in total

1.  Comparison of dose calculation methods for brachytherapy of intraocular tumors.

Authors:  Mark J Rivard; Sou-Tung Chiu-Tsao; Paul T Finger; Ali S Meigooni; Christopher S Melhus; Firas Mourtada; Mary E Napolitano; D W O Rogers; Rowan M Thomson; Ravinder Nath
Journal:  Med Phys       Date:  2011-01       Impact factor: 4.071

2.  Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy.

Authors:  P T Finger; M Kurli
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

Review 3.  Early anti-VEGF treatment for radiation maculopathy and optic neuropathy: lessons learned.

Authors:  Brittany E Powell; Kimberly J Chin; Paul T Finger
Journal:  Eye (Lond)       Date:  2022-08-16       Impact factor: 4.456

4.  Palladium-103 plaque radiation therapy for macular degeneration: results of a 7 year study.

Authors:  P T Finger; Y P Gelman; A M Berson; A Szechter
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

5.  Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years' experience.

Authors:  Y M Bartlema; J A Oosterhuis; J G Journée-De Korver; R E Tjho-Heslinga; J E E Keunen
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

6.  Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma.

Authors:  Ira Seibel; Dino Cordini; Annette Hager; Johanna Tillner; Aline I Riechardt; Jens Heufelder; Anja M Davids; Matus Rehak; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-07-04       Impact factor: 3.117

7.  Ionizing radiation-induced microRNA expression changes in cultured RGC-5 cells.

Authors:  Kaijun Wang; Meijuan Zhu; Panpan Ye; Guodi Chen; Wei Wang; Min Chen
Journal:  Mol Med Rep       Date:  2015-06-16       Impact factor: 2.952

8.  103Pd versus 125I ophthalmic plaque brachytherapy: preoperative comparative radiation dosimetry for 319 uveal melanomas.

Authors:  Paul T Finger; Di Zhou; Nina Kalach; Ekaterina Semenova; Walter Choi
Journal:  J Radiat Oncol       Date:  2014-04-09

9.  Intravitreal triamcinolone acetate for radiation maculopathy recalcitrant to high-dose intravitreal bevacizumab.

Authors:  Richard I Kaplan; Sonal S Chaugule; Paul T Finger
Journal:  Br J Ophthalmol       Date:  2017-04-17       Impact factor: 4.638

Review 10.  Radiation retinopathy: case report and review.

Authors:  Abha Gupta; Felipe Dhawahir-Scala; Amy Smith; Lorna Young; Steve Charles
Journal:  BMC Ophthalmol       Date:  2007-04-05       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.